9
H index
9
i10 index
267
Citations
Office of Health Economics | 9 H index 9 i10 index 267 Citations RESEARCH PRODUCTION: 15 Articles 47 Papers 13 Books RESEARCH ACTIVITY: 26 years (1994 - 2020). See details. MORE DETAILS IN: ABOUT THIS REPORT: Permalink: http://citec.repec.org/pto443 |
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Adrian Towse. | Is cited by: | Cites to: |
Journals with more than one article published | # docs |
---|---|
The European Journal of Health Economics | 4 |
Health Economics | 4 |
Health Policy | 2 |
International Journal of the Economics of Business | 2 |
PharmacoEconomics | 2 |
Working Papers Series with more than one paper published | # docs |
---|---|
Briefing / Office of Health Economics | 14 |
Monograph / Office of Health Economics | 13 |
Occasional Paper / Office of Health Economics | 6 |
NBER Working Papers / National Bureau of Economic Research, Inc | 2 |
Year | Title of citing document |
---|---|
2023 | Market diffusion of biosimilars in off-patent biologic drug markets across Europe. (2023). Steiner, Isa Maria ; Bohm, Anna-Katharina ; Stargardt, Tom. In: Health Policy. RePEc:eee:hepoli:v:132:y:2023:i:c:s0168851023001033. Full description at Econpapers || Download paper |
2023 | The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets. (2023). Straume, Odd Rune ; Dalen, Dag Morten ; Brekke, Kurt R. In: Journal of Health Economics. RePEc:eee:jhecon:v:90:y:2023:i:c:s0167629623000553. Full description at Econpapers || Download paper |
2023 | Are ideas being fished out?. (2023). Knott, Anne Marie ; Kluppel, Leonardo. In: Research Policy. RePEc:eee:respol:v:52:y:2023:i:2:s004873332200186x. Full description at Econpapers || Download paper |
2023 | . Full description at Econpapers || Download paper |
2023 | Does private health insurance prevent the onset of critical illness and disability in a universal public insurance system?. (2023). Lee, Dong-Hwa ; Kim, Daehwan. In: The Geneva Papers on Risk and Insurance - Issues and Practice. RePEc:pal:gpprii:v:48:y:2023:i:1:d:10.1057_s41288-021-00251-5. Full description at Econpapers || Download paper |
2023 | Mimicking Clinical Trials Using Real-World Data: A Novel Method and Applications. (2023). Basu, Anirban ; Bennette, Caroline Savage ; Bansal, Aasthaa ; Wang, Wei-Jhih. In: Medical Decision Making. RePEc:sae:medema:v:43:y:2023:i:3:p:275-287. Full description at Econpapers || Download paper |
2023 | Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis. (2023). Cipriano, Lauren E ; Goldhaber-Fiebert, Jeremy D. In: Medical Decision Making. RePEc:sae:medema:v:43:y:2023:i:7-8:p:914-929. Full description at Econpapers || Download paper |
2023 | Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?. (2023). Cooper, Sophie ; Glover, David ; Crabb, Nick ; Leonard, Colm ; Perkins, Mark ; Wobbe, Milena ; Bouvy, Jacoline. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:21:y:2023:i:3:d:10.1007_s40258-022-00786-1. Full description at Econpapers || Download paper |
2023 | Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments. (2023). Drummond, Michael ; Facey, Karen ; Whittal, Amanda ; Upadhyaya, Sheela ; Meregaglia, Michela ; Morel, Thomas ; Lloyd, Andrew J ; Nicod, Elena. In: The Patient: Patient-Centered Outcomes Research. RePEc:spr:patien:v:16:y:2023:i:1:d:10.1007_s40271-022-00598-4. Full description at Econpapers || Download paper |
Year | Title | Type | Cited |
---|---|---|---|
In: . [Full Text][Citation analysis] | paper | 0 | |
2017 | Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation In: Health Policy. [Full Text][Citation analysis] | article | 8 |
1999 | Is disease management relevant in Europe: some evidence from the United Kingdom In: Health Policy. [Full Text][Citation analysis] | article | 0 |
2011 | Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement In: NBER Working Papers. [Full Text][Citation analysis] | paper | 16 |
2015 | Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement.(2015) In: Health Economics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 16 | article | |
2012 | Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context In: NBER Working Papers. [Full Text][Citation analysis] | paper | 20 |
2015 | Value?Based Differential Pricing: Efficient Prices for Drugs in a Global Context.(2015) In: Health Economics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 20 | article | |
2014 | What is the Role of HTA for Biosimilars? In: Briefing. [Full Text][Citation analysis] | paper | 1 |
2008 | The Market for Biosimilars: Evolution and Policy Options In: Briefing. [Full Text][Citation analysis] | paper | 7 |
2006 | Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds In: Briefing. [Full Text][Citation analysis] | paper | 0 |
1997 | Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry In: Briefing. [Full Text][Citation analysis] | paper | 2 |
1998 | From Efficacy to Cost-Effectiveness In: Briefing. [Full Text][Citation analysis] | paper | 3 |
2003 | Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help? In: Briefing. [Full Text][Citation analysis] | paper | 1 |
2016 | How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
2017 | Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies In: Briefing. [Full Text][Citation analysis] | paper | 1 |
2017 | How can HTA meet the needs of health system and government decision makers? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
2017 | Transferability of HTA In: Briefing. [Full Text][Citation analysis] | paper | 0 |
2017 | HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
2017 | Incentives for New Drugs to Tackle Anti-Microbial Resistance In: Briefing. [Full Text][Citation analysis] | paper | 1 |
2017 | Additional Elements of Value for Health Technology Assessment Decisions In: Briefing. [Full Text][Citation analysis] | paper | 3 |
2017 | Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
2014 | The Expanding Value Footprint of Oncology Treatments In: Consulting Report. [Citation analysis] | paper | 4 |
2011 | The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response In: Consulting Report. [Full Text][Citation analysis] | paper | 3 |
2010 | Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe In: Consulting Report. [Full Text][Citation analysis] | paper | 1 |
2009 | Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Report. [Full Text][Citation analysis] | paper | 0 |
2006 | Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Report. [Full Text][Citation analysis] | paper | 0 |
2015 | Data Governance Arrangements for Real-World Evidence In: Consulting Report. [Full Text][Citation analysis] | paper | 2 |
2016 | Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making In: Consulting Report. [Full Text][Citation analysis] | paper | 2 |
2016 | Four Case Studies to Explore the Added Value of Oxford AHSN In: Consulting Report. [Full Text][Citation analysis] | paper | 0 |
2016 | Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Report. [Full Text][Citation analysis] | paper | 0 |
2017 | Policy Options for Formulary Development in Middle-income Countries In: Consulting Report. [Full Text][Citation analysis] | paper | 1 |
2017 | Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? In: Consulting Report. [Full Text][Citation analysis] | paper | 3 |
2018 | Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe” In: Consulting Report. [Full Text][Citation analysis] | paper | 0 |
2018 | Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Report. [Full Text][Citation analysis] | paper | 2 |
2012 | The R&D Cost of a New Medicine In: Monograph. [Full Text][Citation analysis] | book | 24 |
2011 | New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options In: Monograph. [Full Text][Citation analysis] | book | 3 |
2010 | Biosimilars: How Much Entry and Price Competition Will Result? In: Monograph. [Full Text][Citation analysis] | book | 3 |
2008 | The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way In: Monograph. [Full Text][Citation analysis] | book | 2 |
2006 | Economic Post-Launch Studies: Matching the Desirable with the Feasible In: Monograph. [Full Text][Citation analysis] | book | 1 |
1995 | Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS In: Monograph. [Full Text][Citation analysis] | book | 2 |
1995 | Industrial Policy and the Pharmaceutical Industry In: Monograph. [Full Text][Citation analysis] | book | 1 |
1995 | Value of the Pharmaceutical Industry to the UK Economy In: Monograph. [Full Text][Citation analysis] | book | 0 |
1997 | Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada? In: Monograph. [Full Text][Citation analysis] | book | 2 |
1999 | Disease Management, the NHS and the Pharmaceutical Industry In: Monograph. [Full Text][Citation analysis] | book | 0 |
2002 | Cost-Effectiveness Thresholds: Economic and ethical issues In: Monograph. [Full Text][Citation analysis] | book | 22 |
2002 | Influencing Prescribing in a Primary Care Led NHS In: Monograph. [Full Text][Citation analysis] | book | 0 |
2002 | Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty In: Monograph. [Full Text][Citation analysis] | book | 4 |
2013 | Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold In: Occasional Paper. [Full Text][Citation analysis] | paper | 12 |
2012 | The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation? In: Occasional Paper. [Full Text][Citation analysis] | paper | 2 |
2011 | Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Paper. [Full Text][Citation analysis] | paper | 2 |
2010 | New Drugs to Tackle Antimicrobial Resistance: EU Policy Options In: Occasional Paper. [Full Text][Citation analysis] | paper | 1 |
2014 | Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies? In: Occasional Paper. [Full Text][Citation analysis] | paper | 0 |
2015 | International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa In: Occasional Paper. [Full Text][Citation analysis] | paper | 0 |
2013 | Exploring the link between health and wealth in decision making In: Research Paper. [Full Text][Citation analysis] | paper | 0 |
2012 | Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Paper. [Full Text][Citation analysis] | paper | 4 |
2011 | Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches In: Research Paper. [Full Text][Citation analysis] | paper | 0 |
2011 | Incentives for R&D for New Antimicrobial Drugs In: Research Paper. [Full Text][Citation analysis] | paper | 0 |
2010 | Using QALYs in Cancer: Review of the Methodological Limitations In: Research Paper. [Full Text][Citation analysis] | paper | 12 |
2016 | Uncertainty and Risk in HTA Decision Making In: Research Paper. [Full Text][Citation analysis] | paper | 2 |
2017 | Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value In: Research Paper. [Full Text][Citation analysis] | paper | 3 |
2017 | Macro Evaluation of the NIHR Oxford Biomedical Research Centre In: Research Paper. [Full Text][Citation analysis] | paper | 0 |
2018 | Real World Evidence for Coverage Decisions: Opportunities and Challenges In: Research Paper. [Full Text][Citation analysis] | paper | 7 |
2018 | Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions In: Research Paper. [Full Text][Citation analysis] | paper | 0 |
2015 | Multi-indication Pricing: Pros, Cons and Applicability to the UK In: Seminar Briefing. [Full Text][Citation analysis] | paper | 8 |
2016 | Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria In: Oxford Review of Economic Policy. [Full Text][Citation analysis] | article | 0 |
2012 | Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 15 |
2014 | Orphan drugs policies: a suitable case for treatment In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 11 |
2004 | Genetic screening, health care and the insurance industry In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 3 |
2006 | The desirability and feasibility of economic studies of drugs post-launch In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 1 |
2013 | Operationalizing Value-Based Pricing of Medicines In: PharmacoEconomics. [Full Text][Citation analysis] | article | 14 |
2016 | Biosimilars: How Can Payers Get Long-Term Savings? In: PharmacoEconomics. [Full Text][Citation analysis] | article | 8 |
2011 | Incentives for R&D for New Antimicrobial Drugs In: International Journal of the Economics of Business. [Full Text][Citation analysis] | article | 0 |
2015 | European Union Pharmaceutical Markets: A Case for Differential Pricing? In: International Journal of the Economics of Business. [Full Text][Citation analysis] | article | 9 |
1994 | The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0?333?58579?8 In: Health Economics. [Full Text][Citation analysis] | article | 0 |
1999 | Medical negligence and the NHS: an economic analysis In: Health Economics. [Full Text][Citation analysis] | article | 8 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated December, 10 2023. Contact: CitEc Team